Seelos Therapeutics Doses the First Amyotrophic Lateral Scle

- The Expanded Access Program is funded by a grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS for ALS patients who... | April 4, 2023

Related Keywords

New York , United States , Anthony Marciano , Mike Moyer , Human Services , Drug Administration , Nasdaq , Partnership For Rare Neurodegenerative Diseases , Exchange Commission , Lifesci Advisors , National Institutes Of Health , Department Of Health , Prnewswire Seelos Therapeutics Inc , National Institute Of Neurological Disorders , Access Program , Seelos Therapeutics Inc , Expanded Access Program , National Institute , Neurological Disorders , Accelerating Access , Critical Therapies , Public Law , National Institutes , Public Private Partnership , Rare Neurodegenerative Diseases , Transcription Factor , Amyotrophic Lateral Sclerosis , Acute Suicidal Ideation , Major Depressive Disorder , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Sci Advisors , Seelos Therapeutics , Nc Stock Exchange , News , Information , Press Release , The , Xpanded , Access , Program , Us , Funded , Y , Rant , Rom , Ational , Institute , F , Neurological , Disorders , End , Stroke , Under , Ccelerating , O , Critical , Therapies , Or , Ls , Atients Seel Us81577f1093 ,